- Guide to PHARMACOLOGY
Synonyms: example 1 [WO2020051105A1]
Compound class: Synthetic organic
Comment: The chemical structure for this Janus kinase inhibitor was obtained from the WHO's special release of proposed INNs for COVID-related therapeutics that was published in October 2020, with the proposed INN being nezulcitinib. The structure is a match to example 1 as claimed in Theravance's 2020 patent WO2020051105A1. Analysis of Theravance's pipeline webpage and ClinicalTrials.gov suggests that this is likely to be their clinical lead TD-0903, which they identify as a lung-selective JAK inhibitor, since TD-0903 had begun evaluation in COVID-19 patients. At the point of creating this entry (Nov 2020) there had been no formal name>structure disclosure. We will update this as further details become available.
In June 2021, Theravance announced that top-line results from patients with confirmed COVID-19 associated acute lung injury and impaired oxygenation, showed no statistically significant difference between nezulcitinib and placebo groups in terms of primary or secondary outcomes.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|We speculate that this compound is TD-0903, which is a JAK kinase inhibitor that can be delivered directly to the lungs in a nebulised form. TD-0903 is being evaluated for reduction/prevention of inflammatory lung damage. It has progressed to Phase 1 clinical trial for idiopathic pulmonary fibrosis (IPF; NCT04589260), and Phase 2 for acute lung injury/lung inflammation in patents with COVID-19 (NCT04402866).|